Cargando…
Interleukin-17 promotes the development of cisplatin resistance in colorectal cancer
Cisplatin (DDP)-based anticancer therapy is an important chemotherapeutic strategy for the treatment of colorectal cancer. However, its beneficial effect is largely compromised by adverse reactions, and more importantly, by the development of drug resistance. Therefore, it is crucial to determine th...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313016/ https://www.ncbi.nlm.nih.gov/pubmed/30655852 http://dx.doi.org/10.3892/ol.2018.9645 |